Previous 10 | Next 10 |
Spruce Biosciences ( NASDAQ: SPRB ) has raised approximately $53.6M in a private placement financing . Under the securities purchase agreement, the investors have agreed to purchase around 16.1M shares of the company’s common stock and accompanying warrants to purchase up t...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that it has entered into a definitive securities purchase agreement for a pri...
Summary After an extraordinarily tough 2022, January 2023 was jubilant and a great month for bulls. The Russell 2000 was up 9.8% and I'm happy to report I posted a +21% total return, during the month of January 2023. This piece mostly discusses my numerous mistakes, notably on the p...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will presen...
Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) Anticipated in 2H 2023 Amendment to Phase 2 CAHptain Clinical Trial in Pediatric Classic CAH Enhances Study Design; Topline Data from Adolescents Anticipated in 2H 2023 Topline Data in Phase 2 ...
Spruce Biosciences ( NASDAQ: SPRB ) on Thursday said it had entered into a licensing agreement with Japan's Kaken Pharmaceutical ( OTCPK:KKPCF ) to develop and commercialize its therapy tildacerfont for the treatment of congenial adrenal hyperplasia (CAH). CAH is a group of geneti...
Partnership aims to accelerate global development and commercialization plans for tildacerfont to address worldwide unmet medical need in congenital adrenal hyperplasia (CAH) Deal advances strategy to partner tildacerfont commercial rights outside the United States Spruce to r...
Spruce Biosciences press release ( NASDAQ: SPRB ): Q3 GAAP EPS of -$0.48 beats by $0.06 . Cash, Cash Equivalents and Investments: Cash, cash equivalents and short-term investments as of September 30, 2022, were $90.4 million. For further details see: Spruce B...
CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment Appointment of Saba Sile, M.D., as Vice President of Clinical Development Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developin...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming inves...
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...